必贝特：BEBT-701 临床试验申请获国家药品监督管理局批准

Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for its innovative drug BEBT-701, which targets both AGT and PCSK9 for the treatment of mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol [1] Group 1 - The drug BEBT-701 is a globally first-of-its-kind small interfering RNA (siRNA) medication [1] - The approval allows the company to initiate Phase I-II clinical trials for BEBT-701 [1] - The development of the drug involves a lengthy research cycle, multiple approval stages, and significant investment, leading to various uncertainties [1]